drugset / Trial / NCT01543152
Dose Escalation Study of Cyclophosphamide in HIV-Infected Subjects on HAART Receiving SB-728-T
Non-randomizedSequentialOpen-labelTreatment
Summary
The purpose of the study is to evaluate the safety, tolerability and effect on HIV viral load, of escalating doses of cyclophosphamide administered 1 day prior to SB-728-T infusion.
Timeline
- Start
- 2011-12
- Primary completion
- 2017-07-07
- Completion
- 2017-07-07
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | Cyclophosphamide | Other / unclassified | 200 mg | Intravenous |
| Subject | Cyclophosphamide | Other / unclassified | 500 mg/m2 | Intravenous |
| Subject | Cyclophosphamide | Other / unclassified | 1000 mg/m2 | Intravenous |
| Subject | Cyclophosphamide | Other / unclassified | 1500 mg/m2 | Intravenous |
| Subject | Cyclophosphamide | Other / unclassified | 2000 mg/m2 | Intravenous |
| Subject | SB-728-T | Cell therapy | 5e+09 cells | — |
| Subject | SB-728-T | Cell therapy | 3e+10 cells | — |